1. Tumor initiation
Lung cancer can begin when lung epithelial cells accumulate genetic or epigenetic alterations that disrupt normal growth control, DNA repair, cell death and differentiation.
Lung cancer biology describes how normal lung cells acquire molecular changes, escape growth control, interact with the immune system, remodel their surrounding microenvironment and may invade or spread to distant organs.
Lung cancer biology explains the cellular and molecular processes that allow lung tumors to begin, grow, survive, resist therapy, interact with immune cells and potentially metastasize.
Lung cancer can begin when lung epithelial cells accumulate genetic or epigenetic alterations that disrupt normal growth control, DNA repair, cell death and differentiation.
Altered cells that gain survival or growth advantages can expand into tumor cell populations. These populations may contain different subclones with different biological behavior.
Tumor cells interact with fibroblasts, immune cells, blood vessels, extracellular matrix and inflammatory signals. This tumor microenvironment can influence growth, invasion and resistance.
Lung tumors are not only masses of cancer cells. They are biological ecosystems involving oncogenic signaling, immune escape, angiogenesis, hypoxia, inflammation and metastatic potential.
Alterations in genes such as EGFR, KRAS, ALK, ROS1, BRAF, MET, RET and NTRK can activate pathways that promote survival and proliferation.
Tumor cells may use immune checkpoint pathways such as PD-1/PD-L1 signaling to reduce anti-tumor immune responses.
Growing tumors require oxygen and nutrients. Hypoxic conditions and VEGF-related signaling can support new blood vessel formation.
Tumor cells may acquire invasive features, remodel extracellular matrix and spread through lymphatic or blood vessels.
Lung cancer is commonly divided into non-small cell lung cancer and small cell lung cancer. These groups differ in histology, molecular features, growth behavior and research focus.
NSCLC includes adenocarcinoma, squamous cell carcinoma and large cell carcinoma. Molecular research often focuses on EGFR, KRAS, ALK, ROS1, BRAF, MET, RET, NTRK, HER2/ERBB2 and PD-L1.
SCLC is frequently studied for rapid proliferation, neuroendocrine biology, TP53/RB pathway disruption, DNA damage response, immune evasion and therapy resistance mechanisms.
Biomarkers help researchers classify tumor biology, study signaling pathways, understand immune interactions and investigate experimental response mechanisms.
Receptor tyrosine kinase signaling, proliferation, survival and mutation-driven lung adenocarcinoma biology.
RAS/MAPK signaling, oncogenic growth, metabolic rewiring, resistance biology and tumor progression.
Fusion-driven kinase signaling, molecular subtype classification and pathway activation studies.
Immune checkpoint biology, T-cell interaction, tumor immune escape and immuno-oncology research.
Angiogenesis, vascular remodeling, hypoxia-associated signaling and tumor nutrient supply.
DNA damage response, genomic instability, apoptosis regulation and cell-cycle control.
The tumor microenvironment includes immune cells, stromal cells, blood vessels, extracellular matrix, cytokines, chemokines and metabolic stress signals around tumor cells.
T cells, macrophages and other immune cells can either attack tumor cells or become suppressed by tumor-associated signals.
Fibroblasts can remodel matrix, support invasion and influence inflammatory signaling.
Matrix stiffness, collagen remodeling and tissue architecture can influence invasion and immune infiltration.
Angiogenesis supports oxygen and nutrient access, while abnormal vessels can contribute to hypoxia.
Use open-access or permission-cleared figures. Do not copy ScienceDirect or ResearchGate figures directly unless the figure license explicitly allows reuse.
Recommended source: NIH / PubMed Central open-access lung cancer reviews. These are safer for educational linking and sometimes figure reuse, depending on license.
Open NSCLC tumor biology reviewRecommended source: open-access reviews about lung tumor microenvironment, immune cells, fibroblasts, vessels and extracellular matrix.
Open lung TME reviewLink to the article page only, or request permission for figure reuse. Avoid downloading and re-uploading figures without license confirmation.
View ResearchGate article page
Lung cancer biology is the study of how lung tumor cells arise, grow, survive, interact with the immune system, remodel the tumor microenvironment, invade tissues and spread. It includes genetic mutations, oncogenic signaling, immune escape, angiogenesis, inflammation, hypoxia and metastasis.
Important pathways include EGFR signaling, KRAS/MAPK signaling, ALK and ROS1 fusion signaling, PI3K/AKT signaling, DNA damage response, PD-1/PD-L1 immune checkpoint signaling, VEGF-driven angiogenesis and epithelial–mesenchymal transition.
The tumor microenvironment influences how lung tumors grow, evade immune attack, recruit blood vessels, invade tissue and resist therapy. It includes immune cells, fibroblasts, endothelial cells, matrix proteins and soluble inflammatory signals.
Common lung cancer biology biomarkers include EGFR, KRAS, ALK, ROS1, BRAF, MET, RET, NTRK, HER2/ERBB2, TP53, PD-L1, VEGF and Ki-67.
Search-optimized scientific answers for students, researchers and AI discovery.
Lung cancer cells may grow because genetic and epigenetic alterations activate growth pathways, disable tumor suppressor mechanisms, reduce apoptosis and support uncontrolled proliferation.
A driver mutation is a molecular alteration that contributes to tumor growth or survival. Examples studied in lung cancer include EGFR mutations, KRAS mutations and ALK or ROS1 rearrangements.
Lung tumors may suppress immune activity through mechanisms such as PD-1/PD-L1 checkpoint signaling, immunosuppressive cytokines, regulatory immune cells and exclusion of tumor-infiltrating lymphocytes.
The tumor microenvironment is the ecosystem around tumor cells, including immune cells, fibroblasts, blood vessels, extracellular matrix and molecular signals.
No. This page is for educational and research information only. It does not replace medical consultation, diagnosis or treatment.
Recommended references for lung cancer biology, tumor microenvironment and biomarkers.